This medicine is authorised for use in the European Union.


Amvuttra is a medicine used to treat polyneuropathy (nerve damage) caused by hereditary transthyretin-mediated (hATTR) amyloidosis, a disease in which abnormal proteins called amyloids build up in tissues around the body including around the nerves.

Amvuttra is used in adult patients in the first two stages of the nerve damage (stage 1, when the patient has weakness in the legs but is able to walk unaided, and stage 2, when the patient can still walk but needs help).

hATTR amyloidosis is rare, and Amvuttra was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 25 May 2018. Further information on the orphan designation can be found here.

Amvuttra contains the active substance vutrisiran.

This EPAR was last updated on 10/01/2023

Authorisation details

Product details
Agency product number
Active substance
vutrisiran sodium
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Amyloid Neuropathies, Familial
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.


This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Alnylam Netherlands B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Antonio Vivaldistraat 150
Cross Towers, 20th floor
1083 HP Amsterdam
The Netherlands

Product information

10/01/2023 Amvuttra - EMEA/H/C/005852 - IB/0002

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other nervous system drugs

Therapeutic indication

Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Assessment history

Related content

How useful was this page?

Add your rating
1 rating